Polycystic Ovary Syndrome: Its Genetics and Treatments
Polycystic Ovary Syndrome: Its Genetics and Treatments
DOI:
https://doi.org/10.55184/ijpas.v72i1.29Keywords:
Polycystic ovary syndrome (PCOS), Anovulation, Infertility, Hyperandrogenism, Hirsutism, Metformin, ClomipheneAbstract
Polycystic ovary syndrome (PCOS) is an endocrinopathy common among women of reproductive age. Some women with PCOS have cysts on their ovaries. That’s why it’s called “polycystic.” But the name is misleading because many women with PCOS don’t have cysts. Women with PCOS may have infrequent or prolonged menstrual periods or excess male hormone (androgen) levels. It is characterized by anovulation, infertility, hyperandrogenism, and frequently insulin resistance. Although the role of genetic factors in PCOS is strongly supported, the genes that are involved in the etiology of the syndrome have not been fully investigated until now, as well as the environmental contribution in their expression. Some genes have shown altered expression suggesting that the genetic abnormality in PCOS affects signal transduction pathways controlling steroidogenesis, steroid hormones action, gonadotrophin action and regulation, insulin action and secretion, energy homeostasis, chronic inflammation and others. Because the primary cause of PCOS is unknown, treatment is directed at the symptoms. Insulin-sensitizing agents are indicated for most women with polycystic ovary syndrome because they have positive effects on insulin resistance, menstrual irregularities, anovulation, hirsutism, and obesity. Metformin has the most data supporting its effectiveness. Rosiglitazone and pioglitazone are also effective for ameliorating hirsutism and insulin resistance. Metformin and clomiphene, alone or in combination, are first-line agents for ovulation induction. Insulin-sensitizing agents, oral contraceptives, spironolactone, and topical eflornithine can be used in patients with hirsutism.
References
Amiri M, Ramezani Tehrani F, Nahidi F, Bidhendi Yarandi R, Behboudi- Gandevani S, Azizi F. (2017): Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. Clin Endocrinol (Oxf)., 87(3), 217–30.
Atay V, Cam C, Muhcu M, Cam M, Karateke A. (2006): Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res., 34(1), 73–76.
Azziz R, Bradley E L Jr, Potter H D, Boots L R. (1995): Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 17,20-lyase dysregulation. J Clin Endocrinol Metab., 80, 400-405.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale H F, Futterweit W, et al. (2009): The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril., 91(2), 456–88.
Azziz R, Carmina E, Dewailly D, et al. (2006): Position statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome. An Androgen Excess Society guideline. J Clin Edocrinol Metab., 91, 4237–4245.
Azziz R, Woods K S, Reyna R, Key T J, Knochenhauer E S, Yildiz B O. (2004): The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab., 89(6), 2745-2749.
Bhattacharya S M, Jha A. (2010): Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS). Fertil Steril., 94(1), 357-359.
Cataldo N A, Abbasi F, McLaughlin T L et al. (2006): Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Reprod., 21(1), 109–120.
Celik C, Tasdemir N, Abali R, Bastu E, Yilmaz M. (2014): Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study. Fertil Steril., 101(4), 1123-1128.
Chen S, Besman M J, Sparkes R S et al.(1988): Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA., 7, 27-38.
Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. (2007): Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev., (1), CD005552.
Diamanti-Kandarakis E, Kandarakis H, Legro R S. (2006): The role of genes and environment in the etiology of PCOS. Endocrine., 30, 19–26.
Endocrinology., 254-255, 146-153.
Erickson G F, Hsueh A J W, Quigley M E, Rebar R W, Yen S S. (1979): Functional studies of aromatase activity in human granulose cells from normal and polycystic ovaries. J Clin Endocrinol Metab., 49, 514-519.
Escobar-Morreale H F, San Millan J L, Smith R R, Sancho J, Witchel S F.(1999): The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotypegenotype correlations. Fertil Steril., 55, 629-638.
Escobar-Morreale H, Pazos F, Potau N, Garcia-Robles R, Sancho J M, Varela C. (1994): Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperadrogenism: role of adrenal and ovarian cytochrome P450c17α. Fertil Steri., 62, 521-530.
Farquhar C, Lee O, Toomath R, Jepson R. (2003): Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev.,(4), CD000194.
Franks S. (1995): Polycystic ovary syndrome. N Engl J Med., 333,853–861.
Gharani N, Waterworth D M, Williamson R, Franks S. (1996): 5’polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J Clin Endocrinol Metab., 81, 41-74.
Gilep A A, Sushko T A, Usanov S A. (2000): At the crossroads of steroid hormone biosynthesis: the role, substrate specificity and evolutionary development of CYP17. Biochim Biophys Acta., 1814, 200–209.
Glintborg D, Hermann A P, Brusgaard K, Hangaard J, Hagen C, Andersen M. (2005): Significantly higher adrenocorticotropinstimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J Clil Endocrinol Metab., 90, 1347-1353.
Glueck C J, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. (2003): Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism., 52(7), 908-915.
Glueck C J, Wang P, Fontaine R, Tracy T, Sieve-Smith L. (1999): Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism., 48(4), 511–519.
Harada N, Ogawa H, Shozu M, Yamada K. (1992): Genetic studies to characterize the origin of the mutation in placental aromatase deficiency. Am J Hum Gen., 51, 666-672.
Horikawa Y, Oda N, Cox N J et al. (2001): Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet., 27, 146–155.
Horikawa Y, Oda N, Cox N J. (2000): Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet., 26, 163–175.
Horikawa Y, Oda N, Cox N J. (2002): Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet., 27, 160–172.
Huhtaniemi I, Alevizaki M. (2006): Gonadotrophin resistance. Best Pract Res Clin Endocrinol Metab., 20, 561–576.
Ibrahim Esinler D A, Otegen U, Alikasifoglu M, Yarali H. (2008): Ergul Tuncbilek CYP1A1 gene polymorphism and polycystic ovary syndrome. Reprod BioMed., 16(3), 356–60.
in adolescent girls with polycystic ovarian syndrome. J Pediatr., 138, 38–44.
Ito Y, Fisher C R, Conte F A, Grumbach M M, Simpson E R. (1993): Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proceedings of the National Academy of Sciences of the United States of America., 90, 11673-11677.
Jakimiuk A J, Weitsman S R, Brzechffa P R, Magoffin D A. (1998): Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod., 4, 1-8.
Kahsar-Miller M, Boots LR, Bartolucci A, Azziz R. (2004): Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic
Karoli R, Fatima J, Chandra A, Gupta U, Islam F U, Singh G. (2013): Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci., 6(1), 9-14.
Kashyap S, Wells G A, Rosenwaks Z. (2004): Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod., 19(11), 2474–2483.
Khomami M B, Tehrani F R, Hashemi S, Farahmand M, Azizi F. (2015): Of PCOS symptoms, hirsutism has the most significant impact on the quality of life of Iranian women. PLoS One., 10(4), e0123608.
Kim N K, Nam Y S, Ko J J, Chung H M, Chung K W, Cha K Y. (2001): The luteinizing hormone b-subunit exon 3(Gly102Ser) gene mutation is rare in Korean women with endometriosis and polycystic ovary syndrome. Fertil Steril., 75, 1238–1239.
Legro R S, Arslanian S A, Ehrmann D A et al. (2013): Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clini¬cal practice guideline. J Clin Endocrinol Metab., 98(12), 4565-4592.
Legro R S, Arslanian S A, Ehrmann D A et al. (2013): Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clini¬cal practice guideline. J Clin Endocrinol Metab., 98(12), 4565-4592.
Legro R S, Arslanian S A, Ehrmann D A, et al. (2013): Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab., 98(12), 4565-4592.
Legro R S, Brzyski R G, Diamond M P et al. (2014): NICHD Reproductive Medi¬cine Network. Letrozole versus clomiphene for infertility in the polycys¬tic ovary syndrome. N Engl J Med., 371(2), 119-129.
Lewy V D, Danadian K, Witchel S F, Arslanian S. (2001): Early metabolic abnormalities
Lubahn D B, Joseph D R, Sullivan P M, Willard H F, French F S, Wilson E M. (1988): Cloning of human androgen receptor complementary DNA and localization to the X chromomose. Science., 240, 327-330.
Lubahn D B, Joseph D R, Sullivan P M, Willard H F, French F S, Wilson E M. (1989): Cloning of human androgen receptor complementary DNA and localization to the X chromomose. Science., 242, 227-240.
Mani H, Davies M J, Bodicoat D H, et al. (2015): Clinical characteristics of polycystic ovary syndrome: investigating differences in white and South Asian women. Clin Endocrinol (Oxf)., 83(4), 542-549.
Margrit U. (2006): The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab., 3(2), 145-156.
Marx T L, Mehta A E. (2003): Polycystic ovary syndrome: Pathogenesis and treatment over the short and long term. Cleve Clin J Med., 70(1), 31–33, 36–41, 45.
Moghetti P, Castello R, Negri C et al. (2000): Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab., 85(1), 139–146.
Moll E, Bossuyt P M, Korevaar J C, Lambalk C B, van der Veen F. (2006): Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ., 332(7556), 1485.
Muhammad Akram N R. (2015): Endocrine correlates of polycystic ovary syndrome in pakistani women. J Coll Physicians Surg Pak., 225(1), 22–6.
National Institutes of Health, Department of Health and Human Services. (2008). Beyond Infertility: Polycystic Ovary Syndrome (PCOS). NIH Pub. No. 08-5863.
Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuccu R. (2005): Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? Eur J Obstet Gynecol Reprod Biol., 123(2), 204–211.
Palomba S, Orio F J R, Falbo A et al. (2005): Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab., 90(7), 4068–4074.
Petry C J, Ong K K, Michelmore K F et al. (2005): Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod., 20, 1837-1843.
Petry C J, Ong K K, Michelmore K F et al. (2006): Associations between common variation in the aromatase gene promoter region and testosterone concentrations in two young female populations. J Ster Biochem Mo Biol., 98, 199-206.
Phelan N, O’Connor A, Kyaw-Tun T et al. (2010): Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab., 95(8), 3933-3939.
Picado-Leonard J, Miller W L. (1987): Cloning and sequence of the human gene for P450c17 (steroid 17α-hydroxylase/ 17,20lyase): similarity with the gene for P450c21. DNA., 6, 439-448.
Pinola P, Lashen H, Bloigu A, Puukka K, Ulmanen M, Ruokonen A, Martikainen H, Pouta A, Franks S, Hartikainen A L et al. (2012): Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study. Hum Reprod., 27, 3279–3286.
Ramanujam L N, Liao W X, Roy A C, Loganath A, Goh H H, Ng S C. (1999): Association of molecular variants of luteinizing hormone with menstrual disorders. Clin Endocrinol (Oxf)., 51, 243–246.
Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M. (2011): The metabolic status modulates the effect of metformin on the antimul¬lerian hormone-androgens-insulin interplay in obese women with poly¬cystic ovary syndrome. J Clin Endocrinol Metab., 96(5), E821-E824.
Rosenfield R L. (2015): The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics., 136(6), 1154–65.
Sahin Y, Yirmibes U, Kelestimur F, Aygen E. (2004): The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol., 113(2), 214–220.
Setji T L, Holland N D, Sanders L L, Pereira K C, Diehl A M, Brown A J. (2006): Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab., 91(5), 1741-1747.
Shannon M, Wang Y. (2012): Polycystic ovary syndrome: A common but often unrecognized condition. J Midwifery Womens Health., 57, 221–230.
Simpson E R, Mahendroo M S, Means G D et al. (1994): Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrine Rev., 15, 342-355.
Somani N, Turvy D. (2014): Hirsutism: an evidence-based treatment update. Am J Clin Dermatol., 15(3), 247-266.
Speroff L, Vande Wiele R L. (1971): Regulation of the human menstrual cycle. Am J Obstet Gynecol., 109, 234–47.
Sreenan S K, Zhou Y P, Otani K et al. (2001): Calpains play a role in insulin secretion and action. Diabetes., 50, 2013–2020.
Tang T, Lord J M, Norman R J, Yasmin E, Balen A H. (2012): Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and sub¬fertility. Cochrane Database Syst Rev., (5), CD003053.
Techatraisak K, Conway GS, Rumsby G. (1997): Frequency of a polymorphism in the regulatory region of the 17α-hydroxylase- 17,20-lyase (CYP17) gene in hyperandrogenic states. Clin Endocrinol., 46, 131-134.
Teede H D A, Moran L. (2010): Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med., 8(1), 44-57.
Themmen A P N, Huhtaniemi I T. (2000): Mutations of Gonadotropins and Gonadotropin Receptors: Elucidating the Physiology and Pathophysiology of Pituitary-Gonadal Function. Endocr Rev., 21, 551–583.
Themmen A P. (2005): An update of the pathophysiology of human gonadotrophin subunit and receptor gene mutations and polymorphisms. Reproduction., 130, 263–274.
Urbanek M. (2007): The genetics of polycystic ovary syndrome. Natl Clin Pract Endocrinol Metab., 3, 103–111.
Van Hooff M H, Voorhorst F J, Kaptein M B, Hirasing R A, Koppenaal C, Schoemaker J. (2004): Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod., 19, 383–392.
Van Zuuren E J, Fedorowicz Z, Carter B, Pandis N. (2015): Interventions for hir¬sutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev., (4), CD010334.
Veltman-Verhulst S M, Boivin J, Eijkemans M J, Fauser B J. (2012): Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Hum Reprod Update., 18(6), 638-651.
Veltman-Verhulst S M, Boivin J, Eijkemans M J, Fauser B J. (2013): Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod., 10(1), 40–49.
Venturoli S, Porcu E, Fabbri R, Paradisi R, Gammi L, Passarini M, Orsini L F, Flamigni C. (1994): Ovarian multifollicularity, high LH and androgen plasma levels, and anovulation are frequent and strongly linked in adolescent irregular cycles. Acta Endocrinol., 111, 368–372.
Venturoli S, Porcu E, Fabbri R, Pluchinotta V, Ruggeri S, Macrelli S, Paradisi R, Flamigni C. (1995): Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res., 38, 974–980.
Vgontzas A N, Legro R S, Bixler E O, Grayev A, Kales A, Chrousos G P. (2001): Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab., 86(2), 517-520.
Wildt L, Hausler A, Marshall G, Hutchison J S, Plant T M, Belchetz P E, et al. (1981): Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology., 109, 376–85.
Witchel S F, Aston C E. (2000): The role of heterozygosity for CYP21 in the polycystic ovary syndrome. J Pediatr Endocrinol Metab.,13 (Suppl 5), 1315-1317.
Witchel S F, Lee P A, Suda-Hartman M, Hoffman E P. (1997): Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency. Biochem Mol Med., 62, 151-158.
Witchel S F, Lee P A, Suda-Hartman M, Smith R, Hoffman E P. (1998): 17α-hydroxylase/17,20-lyase dysregulation is not caused by mutations in the coding regions of CYP17. J Pediatr Adol Gynecol., 11, 133-137.
Witchel S F. (2006): Puberty and polycystic ovary syndrome. Molecular and Cellular
Yilmaz M, Karakoc A, Törüner F B et al. (2005): The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol., 21(3), 154–160.
Yilmaz M, Karakoc A, Törüner F B et al. (2006): The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol., 22(3), 149–158.
